Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes

Pharmacogenomics Journal

Volumn 15, Issue 1, 2015, Pages 49-54

  Artuso, R ^a   Provenzano, A ^b   Mazzinghi, B ^a   Giunti, L ^a   Palazzo, V ^b   Andreucci, E ^a   Blasetti, A ^c   Chiuri, R M ^c   Gianiorio, F E ^d   Mandich, P ^d   Monami, M ^e   Mannucci, E ^e   Giglio, S ^a,b,f  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f Fiorgen Foundation for Pharmacogenomics   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; DNA BINDING PROTEIN; RFX6 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ABCC8 GENE; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DNA SEQUENCE; DRUG RESPONSE; FEMALE; GCK GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HNF1ALPHA GENE; HNF1BETA GENE; HNF4ALPHA GENE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IPF1 GENE; MALE; MUTATIONAL ANALYSIS; RFX6 GENE; SCHOOL CHILD; WFS1 GENE; CASE REPORT; DIABETES MELLITUS; GENETICS; INFANT; MUTATION; PEDIGREE; PRESCHOOL CHILD; PROCEDURES; YOUNG ADULT;

ANIMALIA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DNA-BINDING PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INFANT; MALE; MUTATION; PEDIGREE; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84921863497     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.37     Document Type: Article

References (23)

1. Vaxillaire M, Froguel P. Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocr Rev 2008; 29: 254-264.
2. Kavvoura FK, Owen KR. Maturity onset diabetes of the young: clinical characteristics, diagnosis and management. Pediatr Endocrinol Rev 2013; 102: 234-242.
3. Bowman P, Flanagan SE, Edghill EL, Damhuis A, Shepherd MH, Paisey R et al. Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia 2012; 55: 123-127.
4. Edghill EL, Flanagan SE, Patch AM, Boustred C, Parrish A, Shields B et al. Insulin mutation screening in 1044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008; 57: 1034-1042.
5. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 2011; 34: 1878-1884.
6. Bonnefond A, Philippe J, Durand E, Dechaume A, Huyvaert M, Montagne L et al. Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene. PLoS ONE 2012; 7: e37423.
7. Marshall BA, Permutt MA, Paciorkowski AR, Hoekel J, Karzon R, Wasson J et al. Phenotypic characteristics of early Wolfram syndrome. Orphanet J Rare Dis 2013; 8: 64.
8. Smith SB, Qu HQ, Taleb N, Kishimoto NY, Scheel DW, Lu Y et al. Rfx6 directs islet formation and insulin production in mice and humans. Nature 2010; 463: 775-780.
9. Taleb N, Polychronakos C. RFX6 is needed for the development and maintenance of the b-cell phenotype. Islets 2011; 3: 291-293.
10. Mitchell J, Punthakee Z, Lo B, Bernard C, Chong K, Newman C et al. Neonatal diabetes, with hypoplastic pancreas, intestinal atresia and gall bladder hypoplasia: Search for the aetiology of a new autosomal recessive syndrome. Diabetologia 2004; 47: 2160-2167.
11. Ellard S, Lango Allen H, De Franco E, Flanagan SE, Hysenaj G, Colclough K et al. Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. Diabetologia 2013; 56: 1958-1963.
12. Chappell L, Gorman S, Campbell F, Ellard S, Rice G, Dobbie A et al. A further example of a distinctive autosomal recessive syndrome comprising neonatal diabetes mellitus, intestinal atresias and gall bladder agenesis. Am J Med Genet Part A 2008; 146A: 1713-1717.
13. Martinovici D, Ransy V, Vanden Eijnden S, Ridremont C, Pardou A, Cassart M et al. Neonatal hemochromatosis and Martinez-Frias syndrome of intestinal atresia and diabetes mellitus in a consanguineous newborn. Eur J Med Genet 2010; 53: 25-28.
14. Spiegel R, Dobbie A, Hartman C, de Vries L, Ellard S, Shalev SA. Clinical characterization of a newly described neonatal diabetes syndrome caused by RFX6 mutations. Am J Med Genet A 2011; 155A: 2821-2825.
15. Kytö vuori L, Seppänen A, Martikainen MH, Moilanen JS, Kamppari S, Särkioja T et al. WFS1 variants in Finnish patients with diabetes mellitus, sensorineural hearing impairment or optic atrophy, and in suicide victims. J Hum Genet 2013; 58: 495-500.
16. Greeley SA, Naylor RN, Philipson LH, Bell GI. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep 2011; 11: 519-532.
17. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G et al. Largescale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003; 52: 568-572.
18. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42: 579-589.
19. Soyer J, Flasse L, Raffelsberger W, Beucher A, Orvain C, Peers B et al. Rfx6 is an Ngn3-dependent winged helix transcription factor required for pancreatic islet cell development. Development 2010; 137: 203-212.
20. Suzuki K, Harada N, Yamane S, Nakamura Y, Sasaki K, Nasteska D et al. Transcriptional regulatory factor X6 (Rfx6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine K-cells and is involved in GIP hypersecretion in high fat diet-induced obesity. J Biol Chem 2013; 288: 1929-1938.
21. Shao H, Li D, Yang Y, Guo HF, Liu ZY, Si SY et al. The effect of substituted thiophene and benzothiophene derivates on PPARgamma expression and glucose metabolism. J Enzyme Inhib Med Chem 2010; 25: 282-289.
22. Xu H, Murray M, McLachlan AJ. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. Curr Drug Metab 2009; 10: 643-658.
23. Shankar RK, Ellard S, Standiford D, Pihoker C, Gilliam LK, Hattersley A et al. 2013Digenic heterozygous HNF1A and HNF4A mutations in two siblings with childhood-onset diabetes. Pediatr Diabetes 2013; 14: 535-538.